Cancer feature: cnaPANCAN145

ALDH1B1 ANKRD18A ANKRD18A ARHGEF39 ARID3C C9orf131 CA9 CCDC107 CCIN CCL19 CCL21 CCL27 CD72 CLTA CNTFR CREB3 DCAF10 DCTN3 DNAJB5 EXOSC3 FAM166B FAM205A FAM214B FAM221B FANCG FBXO10 FRMPD1 GALT GALT GBA2 GLIPR2 GNE GRHPR HINT2 HRCT1 IGFBPL1 IL11RA KIAA1045 MELK MSMP NPR2 OR13J1 OR2S2 PAX5 PIGO POLR1E RECK RGP1 RNF38 RP11-195F19.5 RP11-613M10.8 RP11-613M10.9 RPP25L RUSC2 SHB SIGMAR1 SIT1 SLC25A51 SPAG8 STOML2 TESK1 TLN1 TMEM8B TOMM5 TPM2 TRMT10B UNC13B VCP ZBTB5 ZCCHC7

Known Driver Genes: FANCG,PAX5

Copy number alternation: loss

Telomerase Inhibitor IX

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer